28th Nov 2005 16:00
Stock Exchange Announcement28 November 2005Shire plc (the "Company")Basingstoke, UK and Philadelphia, US - 28th November, 2005 The Companyannounces that on 28 November 2005 it was notified of the acquisition inLondon, on that day, of ordinary shares in the Company by a Director, andacquisitions by two other Persons Discharging Managerial Responsibilities,following the close of a 27 month offering period under the Shire plc EmployeeStock Purchase Plan. The price of the ordinary shares, which was determined atthe beginning of the offering period, was ‚£4.09.Notification of the acquisition of shares by a Director1,928 ordinary shares of 350p each in the Company were acquired by Mr MatthewEmmens, Chief Executive Officer, being 0.0004% of the issued shares of thatclass. As a result of this transaction, Mr Emmens has a total interest of18,938 ordinary shares in the Company being 0.0038% of the issued shares ofthat class.Notification of the acquisition of shares by other Persons DischargingManagerial Responsibilities1,928 ordinary shares of 350p each in the Company were acquired by Mr GregoryFlexter, Executive Vice President and General Manager, North America, being0.0004% of the issued shares of that class. As a result of this transaction, MrFlexter has a total interest of 1,928 ordinary shares in the Company.1,928 ordinary shares of 350p each in the Company were acquired by Mr John Lee,Executive Vice President, Global Supply Chain and Quality, being 0.0004% of theissued shares of that class. As a result of this transaction, Mr Lee has atotal interest of 1,928 ordinary shares in the Company.For further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system (CNS), gastrointestinal (GI),general products (GP) and human genetic therapies (HGT) - all being areas inwhich Shire has a commercial presence. The structure is sufficiently flexibleto allow Shire to target new therapeutic areas to the extent opportunitiesarise through acquisitions. Shire believes that a carefully selected portfolioof products with a strategically aligned and relatively small-scale sales forcewill deliver strong results. Shire's focused strategy is to develop and marketproducts for specialty physicians. This approach aims to deliver increasedreturns and lower risks. Shire's in-licensing and merger and acquisitionefforts are focused on products in niche markets with strong intellectualproperty protection either in the US or Europe.For further information on Shire, please visit the Company's website:www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forwarding-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risksor uncertainties materialize, Shire plc's results could be materiallyaffected. The risks and uncertainties include, but are not limited to; risksassociated with the inherent uncertainty of pharmaceutical research, productdevelopment, manufacturing and commercialization; the impact of competitiveproducts, including, but not limited to, the impact of those on Shire plc'sAttention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents,including but not limited to, legal challenges relating to Shire plc's ADHDfranchise; government regulation and approval, including but not limited to theexpected product approval dates of DAYTRANA (MTS/METHYPATCH) (ADHD), SPD503(ADHD), SPD465 (ADHD), MESAVANCE (SPD476) (ulcerative colitis), ELAPRASE (I2S)(iduronate-2-sulfase) (Hunter syndrome) and NRP104 (ADHD), including itsscheduling classification by the Drug Enforcement Administration in the UnitedStates; Shire plc's ability to benefit from the acquisition of TranskaryoticTherapies Inc.; Shire plc's ability to secure new products forcommercialization and/or development; and other risks and uncertaintiesdetailed from time to time in Shire plc's and its predecessor registrant ShirePharmaceuticals Group plc's filings with the US Securities and ExchangeCommission, including Shire Pharmaceuticals Group plc's Annual Report on Form10-K for the year ended December 31, 2004. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 5492592 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire